Skip to main content
SpringerLink
Log in
Book cover

Atypische Neuroleptika pp 57–77Cite as

Verträglichkeitsaspekte atypischer Neuroleptika

  • Conference paper

Zusammenfassung

Neuroleptika haben die Behandlung schizophrener Erkrankungen entscheidend verbessert (23). Obwohl die Behandlungserfolge von der kompletten Remission über partielle Besserungen bis hin zur vollständigen Therapieresistenz reichen, profitieren die meisten Patienten in irgendeiner Weise von einer neuroleptischen Behandlung. Unglücklicherweise stellt das Nebenwirkungsprofil der klassischen Neuroleptika einen limitierenden Faktor für die Behandlung dar. Sehr viele Patienten erleben während einer akuten oder chronischen Behandlung unangenehme oder nicht tolerierbare Nebenwirkungen und setzen aus diesen Gründen die notwendige neuroleptische Medikation ab.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baker B, Dorian P, Sandor P, Shapiro C et al. (1997) Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 17: 15–21

    PubMed  CAS  Google Scholar 

  2. Bandelow B, Grohmann R, Rüther E (1997) Unerwünschte Arzneimittelwirkungen bei Neuroleptika: Extrapyramidal-motorische Wirkungen bei klassischen und neuen Neuro-leptika. In: Bandelow B, Rüther E (Hrsg) Therapie mit klassischen und neuen Neuroleptika. Springer, Berlin Heidelberg New York, S 173–184

    Google Scholar 

  3. Beasley CM (1997) Safety of Olanzapine. J Clin Psychiatry 15/2:19–21

    Google Scholar 

  4. Beasley CM, Sanger W, Satterlee G et al. (1996) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacol (Berl) 124:159–167

    CAS  Google Scholar 

  5. Beasley CM, Tollefson G, Tran P et al. (1996) Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsycho-pharmacolgy 14:111–123

    CAS  Google Scholar 

  6. Borison RL, Arvanitis LA, Miller BG, US Seroquel Study Group (1996) ICI 204,636, an Atypical Antipsychotic: Efficacy and Safety in a Multicenter, Placebo-Controlled Trial in Patients with Schizophrenia. J Clin Psychopharmacol 16:158–169

    PubMed  CAS  Google Scholar 

  7. Boyer P,Lecrubier Y,Puech AJ et al. (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72

    PubMed  CAS  Google Scholar 

  8. Broich K, Ehrt U (1997) Sertindol — ein neues „atypisches“ Neuroleptikum. Psychopharma-kotherapie 3:94–100

    Google Scholar 

  9. Buckley NA, Whyte IM, Dawson AH (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33:199–204

    PubMed  CAS  Google Scholar 

  10. Byerly MJ, DeVane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16:177–187

    PubMed  CAS  Google Scholar 

  11. Bymaster FP, Calligaro DO, Falcone JF et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 14: 87–96

    CAS  Google Scholar 

  12. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol (Berl) 99:47–53

    Google Scholar 

  13. Casey DE (1995a) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR (eds) Schizophrenia. Blackwell, Oxford, England, pp 546–565

    Google Scholar 

  14. Casey DE (1995b) Motor and mental aspects of EPS. Int Clin Psychopharmacol 10:105–114

    PubMed  Google Scholar 

  15. Casey DE (1996a) „Seroquel“ (Quetiapine): Preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5/8: 939–957

    Google Scholar 

  16. Casey DE (1996b) Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57/11: 40–45

    Google Scholar 

  17. Ceskova E, Svestka J (1993) Double blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121–124

    PubMed  CAS  Google Scholar 

  18. Chatterton R, Cardy S, Schramm Tm (1996) Neuroleptic malignant syndrome and clozapine monotherapy. N Z J Psychiatry 30/5: 692–693

    Google Scholar 

  19. Chivers JK, Gommeren W, Leysen JE et al. (1988) Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. J Pharm Pharmacol 40:415–421

    PubMed  CAS  Google Scholar 

  20. Chouinard G, Jones B, Remington G et al. (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40

    PubMed  CAS  Google Scholar 

  21. Cohen S, Chiles J, MacNaughton A (1990) Weight gain associated with clozapine. Am J Psychiatry 147: 503–504

    PubMed  CAS  Google Scholar 

  22. Dalkilic A, Grosch WN (1997) Neuroleptic malignant syndrome following initiation of clozapine therapy (letter). Am J Psychiatry 154: 881–882

    PubMed  CAS  Google Scholar 

  23. Deniker P (1984) Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ, Blackwell B (eds) Discoveries in Biological Psychiatry. Baltimore MD. Ayd Medical Communications, pp 155–164

    Google Scholar 

  24. Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41: 369–371

    PubMed  CAS  Google Scholar 

  25. Di Salvo TG, O’Gara PT (1995) Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 18: 285–290

    PubMed  Google Scholar 

  26. Dulz B, Schneider A (1995) Borderline-Störungen. Theorie und Therapie. Schattauer, Stuttgart,S 113–118

    Google Scholar 

  27. Dunn CJ, Fitton A (1996) Sertindole. New Drug Profile. CNS Drugs 5: 224–230

    CAS  Google Scholar 

  28. Ebert D (1997) Quetiapin — ein neues atypisches Neuroleptikum. Fundamenta Psychiatrica 11:79–84

    Google Scholar 

  29. Fleischhacker WW, Barnas C, Stuppäck H et al. (1991) Zotepin vs. Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie. Fortschr Neurol Psychiatr 59:10–14

    PubMed  Google Scholar 

  30. Flugelman MY, Tal A, Pollack S et al. (1985) Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 46: 290–291

    PubMed  CAS  Google Scholar 

  31. Franz M, Gallhofer B (1997) Risperidon. Ein neuer Serotonin-Dopamin-Antagonist zur Behandlung der Schizophrenie. Psychopharmakotherapie 2: 54–58

    Google Scholar 

  32. Fritze J, Bandelow B (1998) QT-Zeit-Verlängerung und das neue, atypische Neuroleptikum Sertindol. Psychopharmakotherapie 3:115–120

    Google Scholar 

  33. Fulop G, Phillips RA, Shapiro AK (1987) ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 144: 673–675

    PubMed  CAS  Google Scholar 

  34. Garson A (1993) How to measure the QT interval — what is normal? Am J Cardiol 72:14B–16B

    PubMed  Google Scholar 

  35. Gerson SL, Meltzer H (1992) Mechanism of clozapine-induced agranulocytosis. Drug Safety 7: 17–25

    PubMed  Google Scholar 

  36. Glazer WM (1997) Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 58 (suppl 10): 18–21

    PubMed  CAS  Google Scholar 

  37. Gleason PP, Conigliaro RL (1997) Neuroleptic malignant syndrome with risperidone. Pharmacotherapy 17: 617–621

    PubMed  CAS  Google Scholar 

  38. Goldstein JM (1996) Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwan GW (eds) Schizophrenia: Breaking Down the Barriers. John Wiley & Sons, New York, pp 177–208

    Google Scholar 

  39. Grohmann R, Rüther E (1994) Neuroleptika. In: Grohmann R, Rüther E, Schmidt LG (Hrsg) Unerwünschte Wirkungen von Psychopharmaka. Springer, Berlin, S 42–133

    Google Scholar 

  40. Guy S, Silke B (1990) The electrocardiogram as a tool for therapeutic monitoring: A critical analysis.J Clin Psychiatry 51: 37–39

    PubMed  Google Scholar 

  41. Haase HJ (1961) Das therapeutische Achsensyndrom neuroleptischer Medikamente und seine Beziehungen zu extrapyramidaler Symptomatik. Fortschr Neurol Psychiatr 29: 245–268

    PubMed  CAS  Google Scholar 

  42. Hewer W, Rost W, Gattaz F (1995) Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 246:1–6

    PubMed  CAS  Google Scholar 

  43. Hinterhuber H, Haring C (1992) Unerwünschte Wirkungen, Kontraindikationen, überdosierungen, Intoxikationen. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka: Antipsychotika. Springer, Heidelberg, Bd 4, S 102–121

    Google Scholar 

  44. Hirsch S, Link CGG, Goldstein JM, Arvantis LA (1996) ICI 204, 636: A new atypical antipsychotic drug. Br J Psychiatry 168 (suppl. 29): 45–56

    Google Scholar 

  45. Itil TM, Soldatos C (1980) Epileptogenic side effects of psychotropic drugs: Practical recommendations. J Am Med Assoc 244:1460–1463

    CAS  Google Scholar 

  46. Jackson T, Ditmanson L, Phibbs B (1997) Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157: 2013–2015

    PubMed  CAS  Google Scholar 

  47. Kammen van DP, McEvoy JP, Targum SD et al. Sertindole Study Group (1995) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharma-cology 124:168–175

    Google Scholar 

  48. Kane JM, Honigfeld G, Singer J (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796

    PubMed  CAS  Google Scholar 

  49. Kapur S, Remington G, Zipursky RB et al. (1995) The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57: 103–107

    Google Scholar 

  50. Keck PE, Pope HG, McElroy SL (1987) Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 144:1344–1346

    PubMed  Google Scholar 

  51. Kiriike N, Maeda Y, Nishiwaki S et al. (1987) Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 22: 99–103

    PubMed  CAS  Google Scholar 

  52. Klieser E, Lehmann E, Tegeler J (1991) Doppelblindvergleich von 3 x 75 mg Zotepin und 3 x 4 mg Haloperidol bei akut schizophrenen Patienten. Fortschr Neurol Psychiatr 59:14–17

    PubMed  Google Scholar 

  53. Klieser E, Lehmann E, Kinzler E, Wurthmann C et al. (1995) Randomized, double blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15:45S–51S

    PubMed  CAS  Google Scholar 

  54. Klimke A, Klieser E (1995) Das atypische Neuroleptikum Clozapin (Leponex®) — aktueller Kenntnisstand und neuere klinische Aspekte. Fortschr Neurol Psychiatrie 5:173–193

    Google Scholar 

  55. Kresse-Hermsdorf M, Müller-Oerlinghausen B (1990) Tricyclic neuroleptic and antidepressant overdose: Epidemiological, electrocardiographic, and clinical features — A survey of 92 cases. Pharmacopsychiatry 23 (suppl): 17–22

    PubMed  Google Scholar 

  56. Kriwisky M, Perry GY, Tarchitsky D et al. (1990) Haloperidol-induced torsades de pointes. Chest 98:482–484

    PubMed  CAS  Google Scholar 

  57. Lamberti JS, Bellnier T, Schwarzkopf SB (1992) Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 149: 689–690

    PubMed  CAS  Google Scholar 

  58. Lawrence KR,Nasraway SA (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature. Pharmacotherapy 17: 531–537

    PubMed  CAS  Google Scholar 

  59. Leadbetter R, Shutty M, Pavalonis D et al. (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149:68–72

    PubMed  CAS  Google Scholar 

  60. Lee H, Ryan J, Mullett G et al. (1994) Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Human Psychopharmacology 9:303–305

    Google Scholar 

  61. Leysen JE, Gommeren W, Eens A et al. (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661–670

    PubMed  CAS  Google Scholar 

  62. Leysen JE, Janssen PMF, Schotte A et al. (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacol (Berl) 112:40–54

    Google Scholar 

  63. Lieberman JA, Alvir JM (1992) A report of clozapine-induced agranulocytosis in the United States. Drug Safety 7:1–2

    PubMed  Google Scholar 

  64. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835

    PubMed  CAS  Google Scholar 

  65. Mason RP, Fischer V (1992) Possible role of free radical formation in drug-induced agranulocytosis. Drug Safety 7:45–50

    PubMed  CAS  Google Scholar 

  66. Mehtonen OP, Aranko K, Malkonen L, Vapaatalo H (1991) A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 84: 58–64

    PubMed  CAS  Google Scholar 

  67. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin pKi values. J Pharmacol Exp Ther 251: 238–246

    PubMed  CAS  Google Scholar 

  68. Meterissian GB (1996) Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 41: 52–54

    PubMed  CAS  Google Scholar 

  69. Möller HJ, Boyer P, Fleurot O, Rein W (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 132: 396–401

    PubMed  Google Scholar 

  70. Moertl D, Heiden A, Porenta G, Kasper S (1998) Kardiovaskuläre Nebenwirkungen bei Neuroleptika-Therapie. Psychopharmakotherapie 3:109–114

    Google Scholar 

  71. Moore NA, Calligaro DO, Wong TD et al. (1993) The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigational Drugs 2:281–293

    Google Scholar 

  72. Müller WE, Tuschl R, Gietzen K (1995) Therapeutische und unerwünschte Wirkungen von Neuroleptika — die Bedeutung von Rezeptorprofilen. Psychopharmakotherapie 4:148–153

    Google Scholar 

  73. Nemeroff CB (1997) Dosing the antipsychotic medication olanzapine.J Clin Psychiatry 58 (suppl 10): 45–49

    PubMed  CAS  Google Scholar 

  74. Otani K, Bondo T, Kaneko S et al. (1992) Steady-state serum kinetics of zotepine. Hum Psychopharmacol 7: 331–336

    Google Scholar 

  75. Parsons M, Buckley NA (1997) Overdose of antipsychotic drugs: Practical management guidelines. CNS Drugs 7: 427–441

    CAS  Google Scholar 

  76. Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726

    PubMed  CAS  Google Scholar 

  77. Pisciotta AV, Konings SA, Ciesemier LL et al. (1992) On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Safety 7: 33–44

    PubMed  Google Scholar 

  78. Puech AJ, Turjanski S, Fleurot O (1996) Amisulpride in the treatment of acute exacerbations of subchronic or chronic schizophrenia: a dose range finding study. Eur Psychiatry 11:280S

    Google Scholar 

  79. Ravin DS, Levenson JW (1997) Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 31: 867–870

    PubMed  CAS  Google Scholar 

  80. Reddig S, Minnema AM, Tandon R (1993) Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 5: 25–27

    PubMed  CAS  Google Scholar 

  81. Roszinsky-Köcher G,Dulz B (1996) Zotepin — ein atypisches Antipsychotikum. Fundamenta Psychiatrica 10: 40–46

    Google Scholar 

  82. Saller CF, Salama AL (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol (Berl) 112: 285–292

    CAS  Google Scholar 

  83. Sanchez C, Arnt J, Dragsted N et al. (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development and Research 22: 239–250

    CAS  Google Scholar 

  84. Schmauss M, Wolff R, Erfurth A, Rüther E (1989) Tolerability of long term clozapine treatment. Psychopharmacology 99:105–108

    Google Scholar 

  85. Schoemaker H, Claustre Y,Fage D et al. (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Pharmacol Exp Ther 280: 83–97

    CAS  Google Scholar 

  86. Seeger TF, Seymour PA, Schmidt AW et al. (1995) Ziprasidone (CP-88.059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101–113

    PubMed  CAS  Google Scholar 

  87. Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 10: 25–33

    PubMed  CAS  Google Scholar 

  88. Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289–294

    PubMed  CAS  Google Scholar 

  89. Skarsfeldt T, Perreghaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 Dopamine neurones in the rat. Eur J Pharmacol 182: 613–614

    PubMed  CAS  Google Scholar 

  90. Snyder S, Greenberg D, Yamamura H (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61

    PubMed  CAS  Google Scholar 

  91. Sokoloff P, Giros B, Martres MP et al. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151

    PubMed  CAS  Google Scholar 

  92. Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden von Clozapin). Pharmakopsychiatr Neuropsychopharmakol 4:182–191

    CAS  Google Scholar 

  93. Stip E, Lussier I, Babai M (1996) Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiat 40: 434–435

    PubMed  CAS  Google Scholar 

  94. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic. Neuropsychopharmacol 14: 97–104

    CAS  Google Scholar 

  95. Street JS, Tamura RN, Sanger TM et al. (1996) Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. In: American Psychiatric Association (eds) New research program and abstracts of the annual meeting of the American Psychiatric Assocication, New York, NY, May 8

    Google Scholar 

  96. Suessbrich H, Schonherr R, Heinemann SH, Attali B et al. (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120: 968–974

    PubMed  CAS  Google Scholar 

  97. Tan HL, Hou CJY, Lauer MR et al. (1995) Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 122: 701–704

    PubMed  CAS  Google Scholar 

  98. Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466–474

    PubMed  CAS  Google Scholar 

  99. Tollefson GD, Beasley CM, Tran PV et al. (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457–465

    PubMed  CAS  Google Scholar 

  100. Tran PV, Dellva MA, Tollefson GD et al. (1997) Extrapyramidal symptoms and tolerability of olanzapine vs haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58: 205–211

    PubMed  CAS  Google Scholar 

  101. Uetrecht JP (1992) Metabolism of clozapine by neutrophils: possible implications for clozapine-induced agranulocytosis. Drug Safety 7: 51–56

    PubMed  CAS  Google Scholar 

  102. Umbricht D, Kane JM (1995) Risperidone: efficacy and safety. Schizophr Bull 21: 593–606

    PubMed  CAS  Google Scholar 

  103. Van de Merwe TJ, Silverstone T, Ankier SI (1984) Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients. Curr Med Res Opin 9: 339–352

    PubMed  Google Scholar 

  104. VanTol HHM, Bunzow JR, Guan H et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614

    PubMed  Google Scholar 

  105. Warner JP, Burnes TR, Henry JA (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93: 311–313

    PubMed  CAS  Google Scholar 

  106. Weaver MG (1997) Olanzapine-pharmacology and clinical evaluation of a new atypical antipsychotic. J Serotonin Res 4:145–157

    CAS  Google Scholar 

  107. Webster P, Wijerame C (1994) Risperidone-induced neuroleptic malignant syndrome. Lancet 344: 1228–1229

    PubMed  CAS  Google Scholar 

  108. Weiler M,Kornhuber J (1992) Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. Nervenarzt 63: 645–655

    Google Scholar 

  109. Wetzel WW, Barnas C, Stuppäck H et al. (1991) Zotepin vs. Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie. Fortschr Neurol Psychiatr 59:10–14

    Google Scholar 

  110. Wetzel H, Szegedi A, Hain C et al. (1995) Seroquel (ICI 204 636), a putative „atypical“ antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacol (Berl) 119: 231–238

    CAS  Google Scholar 

  111. Zimbroff DL, Kane JM, Tamminga CA et al. (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatr 154: 782–791

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bezirkskrankenhaus Augsburg, Dr.-Mack-Straße 1, 86156, Augsburg, Deutschland

    Prof. Dr. M. Schmauß

Authors
  1. Prof. Dr. M. Schmauß
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik mit Konsiliardienst, Großhadern, Klinikum Innenstadt, Nußbaumstraße 7, D-80336, München, Deutschland

    Hans-Jürgen Möller  & Norbert Müller  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Schmauß, M. (1999). Verträglichkeitsaspekte atypischer Neuroleptika. In: Möller, HJ., Müller, N. (eds) Atypische Neuroleptika. Steinkopff. https://doi.org/10.1007/978-3-642-93709-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93709-5_5

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1179-8

  • Online ISBN: 978-3-642-93709-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation